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Haileselassie Tefera, Ms. Human Biology. Haileselassie.tefera@jacks.sdstate.edu
Biology and Microbiology Department, South Dakota State University, Brookings, SD

ABSTRACT: The Hedgehog (Hh) signaling pathway plays a crucial role during embryonic
development as well as tissue maintenances in adults. Deregulated Hh signaling has been
implicated in different diseases and conditions including cancer. Previously, the mechanisms of
Hh signaling pathway and its role in cancer formation have been studied and has led to the
development of therapeutic drugs. Among those agents, vismodegib and sonidegib are FDA
approved drugs to treat basal cell carcinoma and other cancers. Up to date, several hedgehogs
(Hh) signaling inhibitors and drugs have been made and evaluating for cancer treatment. In this
review, I will discuss the mechanisms of action of Hh signaling pathway, targeted components,
and Hh inhibitors and clinical importance as well as side effects, current evidences, and drug
resistance.
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INTRODUCTION
The hedgehog gene was discovered first in 1980’s by Christiane Niisslein Volhard and Eric
Wieschaus when they studied segmentation in Drosophila melanogaster(1). Mutation of this gene

affected the number of segments observed and polarity in fruit fly. After Christiane Niisslein
Volhard and Eric Wieschaus discovery, hedgehog signaling has significantly been studied by
different scientists and numerous efforts have been made to investigate the diseases associated
with hedgehog signaling pathway. The hedgehog pathway plays a crucial role in embryonic
development, cell growth and differentiation and segmentation in vertebrates as well as in
annelid (2, 3). This signaling pathway is responsible for the correct formation of limbs, digits,
brain, bone, oogenesis, spermatogenesis and many other cells and structures during early
embryogenesis (3). In adult vertebrates, the hedgehog signaling pathway is mostly inactive and
involves in tissues and organs(4). Mutations that occur during embryonic development that affect
hedgehog signaling pathway are linked to developmental disorders and mutations that occur
during somatic development in adults associated with multiple forms of cancers (5).

Researchers spent substantial amount of time targeting the hedgehog signaling pathway
inhibitors to develop potential anticancer agents. Smoothened (SMO) is the primary regulatory
protein that many researchers targeted including Ptch1, GLI and developed a lot of Hh signaling
pathway inhibitors. Even if multiple Hh agents have been made, only two drugs get approved by
FDA and the rest needs some type of modification and additional studies in order to use as a
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cancer treatment. These drugs demonstrated and used as monotherapies and others in
combination with other treatments. Most of them showed a promising result upon investigating
on model organisms.

Hedgehog Ligands
The three orthologues that involve in hedgehog signaling pathway in vertebrates are Sonic Hh
(Shh) the best studied pathway, Indian Hh (Ihh) and Dessert Hh (Dhh). Each Hh ligands displays
different expression and function in the cell. For example, sonic hedgehog is very important for
formation of limbs, neural tube, somites, and affects epithelial tissues developments. Indian Hh
signaling is essential for bone growth, chondrocyte development and formation of the primitive
endoderm. Dessert Hh expression mostly limited to gonads and Schwann cells formations (3, 5).
These ligands mediate the Hh signaling pathway at the primary cilium where clusters of
receptors found, and upon activation, signaling cascades takes place during embryogenesis and
tissue homeostasis (3, 6). In the absence or overexpression of these ligands and defect at the
primary cilia, the Hh signaling pathway causes developmental disorders and abnormalities in
tissues and organs. Hh pathway requires primary cilia in order to regulate and cascade molecular

signaling and induce gene transcription(7).

Hedgehog signaling pathway and Key Components
There are many positive and negative regulatory components of hedgehog pathway to transduce
activation and inhibition of signaling pathway. Patched, GLI, smoothened (SMO) and SUFU are
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some of the key components. Protein kinases like protein Kinase A, glycoprotein synthase
Kinase 3 beta, and casein Kinase 1 also play a major role in the signaling and phosphorylation
process of Hh signaling (3, 8). Understanding the basic concepts of Hh signaling pathway
activation and it’s components help to select and develop the appropriate drugs for specific
cancer.

Patched is a 12-span transmembrane Hh receptor protein which has a negative regulatory
function at the primary cilia. It is involved as a negative feedback mechanism to regulate Hh
signaling activity in embryonic cell as well as tissue repairs. In the absence of Hh ligand, this
transmembrane protein placed at the cilia prevents the accumulation of smoothened and therefore
inhibit the Hh signaling pathway (3).

Smoothened (SMO) is a 7-transmembrane G protein-coupled like protein receptor which, leads
to the activation of Hh pathway by activating GLI transcription factors. Smoothened is repressed
by Ptch1 to inhibit Hh pathway (8, 9). Glioma-associated oncogene (GLI) is a transcription
factor that mediates the response of transcription of the target gene. In mammals, GLI 1 and 2
are Hh signaling pathway activators. When these transcriptional activators are phosphorylated by

protein kinases like PKA, GSK3β and CK1, lead to generate a GLIR which is a transcriptional
repressor and results in inhibitions of Hh pathway target gene transcription in the nucleus (3, 911).

SUFU is another intracellular component that negatively controls the activation of Hh signaling
pathway. It directly binds to the GLI protein in the cytoplasm and blocks its activation and
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nuclear localization and forms a repressor protein complex that can suppress the Hh gene
expression (12).

Signaling pathway in the absence of Hh ligands

Hh signaling pathway is not always active in adult vertebrates. In the absence of Hh ligands,
Ptch1 activated and repress smoothened by sitting and preventing its accumulation on the
primary cilia. Primary cilium is where the activation and inhibition of Hh signaling started at the
membrane before series of signaling cascades takes place in the cytoplasm and nucleus. When
SMO inhibited by Ptch1, it cannot dislocate to the cytoplasm and dissociate SUFU-Gli complex.
The SUFU and GLI complex in the cytoplasm then get phosphorylated by PKA, GSK3β and
CK1which lead to proteolytic process to produce repressor protein (3, 13). SUFU is a negative
regulator and suppress GLI and inhibiting its translocation to the nucleus. The SUFU and GLI
complex generates a new repressor protein called GLIR which transport to the nucleus and inhibit
hedgehog signaling target gene expression (3). (Fig 1A below). Along with other Hh key
components, signaling pathway inhibited.

Signaling pathway in the presence of Hh ligands
In the presence of Hh ligand, it’s signaling pathway get activated and affect the cells activity. Hh
ligand first converted to its active form and binds to the Ptch1 which is a 12-transmembrane
protein and Hh ligand receptor (12). The inhibitory effect of Ptch1 removed from the SMO and
then this 7TM translocate to the primary cilia and dissociate Suppressor of Fused (SUFU) and
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GLI complex. SUFU-GLI complex was supposed to generate a repressor protein and inhibit the
Hh signaling that target gene expression in the nucleus but when this complex dissociated, GLI,
a transcription factor activate and translocate to the nucleus to induce a gene transcription for Hh
target genes(3). (see Fig 1 B below). Including many other key components this is the activation
pathway of Hedgehog signaling.

Fig. 1. General hedgehog signaling pathway: Activation and inhibition of hedgehog signaling pathway
by different key components. (A) patch1 inhibit SMO at the primary cilia in the absence of Hh ligands and
SUFU-GLI complex formed. When GLI phosphorylated by PKA, GSK3β and CK1 which generate a GLIR
which in turn inhibit Hh gene expression. (B) In the presence of Hh signaling ligands, Shh, Ihh or Dhh
binds and inhibit Ptch1. SMO activated and dissociate SUFU and GLI complex and no GLIR produced to
suppress transcription but GLI move to the nucleus to induce activation of target gene.
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Molecular mechanisms of Hh ligands and key components
The molecular mechanisms how Hh ligands interact with Ptch1 and inhibitory effect on
smoothened is unclear. Recent study showed that the cytoplasmic tail contributed to inhibitory
function of Ptch1 on smoothened and Hh ligands interaction (13). In this study, when the Cterminus amino acid truncated on the transmembrane segment, Ptch1 activity disrupted and
smoothened suppression relieved and leads to constitutive activation of Hh signaling pathway.
Ptch1 with truncated extracellular loop and normal cytoplasmic tail fully suppressed smoothened
activity but Hh ligands did not bind. This research also discussed truncated tail and loop of
smoothened impaired its accumulation at the cilia and downstream activation of Hh signaling
pathway.

Cancer and Treatments Using Hh Inhibitors
The detailed study of activation and inhibition of the Hh pathway helped researchers to develop
drugs and to turn their attention towards the cancer. Currently, the main target of cancer research
regarding drug therapies including cancer prevention is smoothened. The Hh signaling is able to
maintain cancer stem cells by feeding the surrounding microenvironments of the tumor to grow
so, researchers targeted by inhibiting the over expression of Hh signaling pathway in different
cancer and related diseases to treat the patients (3). Tumor invasion and progression inhibited by
Hh signaling inhibitors in clinical patients and model organism. In some studies the hedgehog
(Hh) pathway expression was limited in normal adults but in cancer cells Hh was overexpressed
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and facilitates the growth of the tumor (14). Basal Cell Carcinoma (BCC) is the most common
skin cancer in human and overexpression of Hh pathway is a key driven pathogenesis.
Vismodegib and sonidegib are the only two FDA approved drugs. Nowadays BCC incidence is
increasing in the world and different drug developers and researchers are doing tremendous
effort to develop therapeutic drugs and showing promising results (15). Advanced BCC patients

usually use vismodegib and sonidegib in combination or separately. As figure 2 indicated, the
overexpression of Hh pathway in BCC tumor show regression and decrease in size after
treatment. These drugs able to promote adaptive immune cells to the tumor microenvironment

(4).

Fig.2. Immune cells infiltration after Hh pathway inhibitors treatments. A biopsy taken from
patients before and after treatment. (A)Immunostaining of patients’ biopsy revealed increaseCD8 cells
in tumor environments. (B) upregulation of MHC class I cells expression in intratumor and peritumoral
area.
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Drugs that targeted Hh signaling pathway
In recent years a major effort has been made and developed many inhibitors that blocked Hh
signaling pathway at different steps. The Hh signaling pathway key components that targeted for
these therapeutic agents are Smoothened, GLI, Hh orthologue and Hhat. As discussed above,
most of the Hh signaling pathway inhibitors are targeted smoothened. Some cancers treated with
single Hh pathway inhibitors and others treated with a combination of Hh antagonist drugs.

Therapeutic drugs target Smoothened

Most of those inhibitors are specifically acted on smoothened to block the expression of Hh
signaling in tumor and its microenvironments (16). Among these therapeutic drugs Vismodegib

and Sonidegib have been approved by Food and Drug Administration (FDA). Saridegib,
Taladegib and Cyclopamine and its derivatives also target SMO receptor.

Vismodegib is a small molecule and the first hedgehog signaling pathway inhibitor which act on
Smoothened protein to prevent its accumulation in primary cilia (17). This inhibitor approved by
FDA for metastatic basal cell carcinoma. In one study involving 704 basal cell carcinoma

patients showed a partial response rates of 62 % and currently Vismodegib is in clinical trials for
other cancers as monotherapy and in combination with other drugs (3, 17). In some clinical trials
of Medulloblastoma patients, Vismodegib showed an ineffective result because of mutation of
SMO protein and in fact its low solubility (12).
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Sonidegib is the second FDA approved smoothened inhibitor for basal cell carcinoma patients
followed by surgery, radiation treatment and or patients who is not candidate for surgery and
radiation (12). Otsuka et al studied 23 patients with basal cell carcinoma after Vismodegib and
Sonidegib treatments(4). They found these drugs altered the tumor cell populations and promote
adaptive immunity in tumor microenviroments. After these therapuatic drugs treatment, the

patients showed influx of some immune cells in the tumor microenviroments (10). Both
Vismodegib and Sonidegib are in clinical trials to treat lung and other solid tumors(3). Figure 3
below showed the modification of the orginal sonidegib compound in order to improve toxicity
and solubility (18) and also chemical structure of vismdegib (19).

I

II
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III

Fig. 3. Modification of sonidegib. 1. Three core regions namely A, B, and C of compound I get
modified. 2. Region A modified with Nitrogen in the pyridine moiety and dimethyl group added to
improve toxicity, Region B modified, and methyl added to increase potency and finally region C
modified with F3CO in order to favor absorption as shown on compound II. R400, R473, and E518 are
drug binding pockets for SMO. Arginine (R) and Glutamic acid (E) are the amino acids associated with
this binding site. Compound III is the first FDA approved drug, vismodegib.

Cyclopamine is naturaly occuring compound and effective smoothened inhibitor which is found
in the corn lily. This compound found in 1950’s in research done due to a lambs born with one
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eye and it tooks scientists about ten years to figured it out (17). Cylopamine has been intensively
studied and demonestrated to inhibit melanoma, colon, pancreatic, prostate, lung and other
cancers but its therapauetic usage as Hh inhibitor for human is limited due to poor property and
its side effects of low solubility in the body under normal condition (3). In order to overcome this
limitation some other cyclopamine derivaties developed which include KAAD cyclopamine and

Saridegib with a potentially improved soubility in model animals but iys clinical trials terminated
due to inefficents clinical benefit and for patients saftey (3, 9).

Therapeutic drugs target Gli

The other target for hedghog signaling pathway inhibitors is Gli transcription factor (3, 9, 20).
This target protein is important to overcome drug resistance property of smoothend. Among the
Gli inhibitors, GANT58 and GANT61 are small molecules and suppressed the proliferation of
rhabdomyosarcoma, prostate, colon, and ovarian cancers and further study showed potential
distruption of Gli phosporaylation and Hh inhibition (3, 21). Arsenic trioxide (ATO) is also Shh
inhibitor by blocking Gli protein and used to treat patients with white blood cells cancer and
currently it is in clinical trials for solid tumors including pancreatic cancer (3, 22).

Therapeutic drugs target Hh Ligands

Hedgehog signaling pathway ligands (Shh, Dhh and Ihh) are also target for therapeutic agents to
block abnormal proliferation of cancerous cells in tumor microenvironments (3, 8, 16). All the
three ligands were able to block by a monoclonal antibody 5E1. 5E1 has been proved to suppress
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pancreatic and medulloblastoma in mouse model. An acyltransferase (Hhat) which is essential
hedgehog (Hh) signaling pathway enzyme targeted by a small molecule RUSKI-43 and RUSKI-

Table 1. Summary of hedgehog signaling pathway inhibitors and its implication in cancer.
201 (3, 23).
Hh inhibitors

Target

Treatment/Repression

Side effects

Vismodegib

SMO

FDA approved for metastatic BCCs

FDA approved, ongoing
clinical trials for other
cancers and Resistance

Cyclopamine

Saridegib

Taladegib

SMO

SMO

SMO

Inhibit Tumor like glioma, melanoma,

Due to low solubility, it is

prostate, colon and lung cancers

not approved by FDA

Ovarian, medulloblastoma and

Potent and detrimental

pancreatic cancer

effects

Medulloblastoma in model animal

Effective only in BCCs
(mice)

Sonidegib

SMO

BCCs (CR)4, lung, and advanced solid

FDA approved, ongoing

tumors.

clinical trials for other
cancers and resistance

Itraconazole

SMO

FDA approved for antifungal disease

Ongoing clinical trials.
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GANT58 & 61

GLI

Prostate, colon and ovarian

Ongoing clinical trials

5E1

Hh ligands

Medulloblastoma and pancreatic

No clinical trial yet

RUSKI-43

Shh, Hhat

Breast and pancreatic tumors

No clinical trial yet

BCC

Under clinical investigation

& PDE4

Glasdegib

SMO

Drug resistance challenges, and recent studies on small molecules
As I discussed above, SMO showed a resistance for vismodegib and sonidegib therapeutic drugs.
It has been a major challenge for FDA approved Hh pathway drug users to overcome the drugresistant property of SMO mutant (12). A recent research was done on Hh inhibitors and Hh
dependent tumors, and they found a promising result for mutant SMO and sonidegib and
vismodegib resistance tumors (24). In this study, a compound called 2’, 4’, 5’, 3, 4pentamethoxychalcone was found to be the most powerful Hh pathway inhibitor by binding at
the same binding site as Cyclopamine. This drug acts on SMO receptor. They farther
investigated on the Hh driven tumors in which constitutive activation of Hh target gene present
and loss of Ptch1 function. Small concentration of this compound was able to decrease the
mRNA levels of the downstream Hh target genes.
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Many cancer patients who took vismodegib and sonidegib treatment showed drug resistance at
the SMO receptor due to its rapid mutation, but this new drug is able to act on drug-resistant
SMO mutant and it will have a potential impact for future cancer treatments. In recent study by
F. Wang et al., derivative of vismodegib found to have a long-acting Hh inhibitor activity
compared to vismodegib itself (25). In this study they synthesized a deuterium-hydrogen

analogue of vismodegib and found to be more stable when administered in mice. As summarized
in table 2 and Figure 4 below, a lot of small molecules and active plant products showed a
significant inhibitory effect on Hh signaling pathway and further study and modification of these
compounds while have great therapeutic treatment for Hh-driven cancers (12, 23, 26-28).

Basal Cell Carcinoma (BCC) is the most common skin cancer in human and overexpression of

Hh pathway is a key driven pathogenesis. Vismodegib and sonidegib are the only two FDA
approved drugs. Nowadays BCC incidence is increasing in the world and different drug
developers and researchers are doing tremendous effort to develop therapeutic drugs and
showing promising results (15). Advanced BCC patients usually use vismodegib and sonidegib
in combination or separately. As figure 3 indicated, the overexpression of Hh pathway in BCC
tumor show regression and decrease in size after treatment. These drugs able to promote adaptive
immune cells to the tumor microenvironment (4).
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Table 2. Summary of recent design of Hh signaling pathway inhibitors. The following small molecules
and natural compounds are new and modified forms of known Hh inhibitors and needs further studies
before clinical trial. These small molecules and active plant products might use as a source for
development of newly synthetic Hh signaling pathway inhibitor.

Compound

Category/Source

Action and Target

Limitation and side effect

Eggmanone

Thiophenes

PDE4/SMO

Low solubility, potent

RUSKI 39, 41,43 and 50

Thiophenes

Hhat/Hhh

Potent and cytotoxicity

Bisamide compounds

pyridines

Kinases

Low solubility and strong bind
with plasm

Tetrahydrothiazolo[5,4-

Pyridine

SMO

High potency and large size

pyridine

SMO

Induce apoptosis, and strong

c] pyridine

Hh003

inhibiting activity in mouse
model compared to Vismodegib
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Pyridine

GRE

18

Hh/Wnt but

Inhibit Wnt and Hh pathway

specific target not

simultaneously

identified

VD3

Vitamin D3

SMO

Promote hypercalcemia

analogs

SANT-2

Benzimidazoles

SMO

High potency

Robotnikinin

Macrolactone

SMO/Shh

Cytotoxic and poor solubility

SMO

Weak affinity

GLI/BCL-2

Good candidates for clinical

analog

LAB687

Biphenyl
derivative

Colubrinic and betulinic

Pentacyclic

acid

triterpenes

Genistein

Natural /plant

GLI1

Needs modification

Curcumin

Natural /plant

Shh, GLI

Needs modification

Resveratrol

Natural /plant

GLI

Needs modification

trial
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Natural /plant

Ihh/GLI

Needs modification

Inorganic

GLI

FDA approved for Leukemia

GLI

Further study

SMO

Under clinical trials

gallate

Arsenic trioxide

compund

Glabrescione B and

Extracted from

Isoflavone

seeds

LEQ-506 and TAK-441

Small molecules
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Fig. 4. Series of different groups of compounds that inhibit Hh signaling pathway. These
chemicals showed a promising result by inhibiting the Hh pathway at different target regions of the
cells. Modification of these compounds might result effective therapeutic drugs for Hh-dependent
cancers.
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Conclusion
The discovery of the Hh pathway played an important role in the understanding of normal
vertebrate development (29). Abnormal activation of Hh is involved in cancer. Most studies

focused on SMO and other key components to inhibit the Hh pathway. In recent years numerous
hedgehogs signaling pathway inhibitors specifically target Smoothened have been came out and
undergo preclinical and clinical trials. These Hh pathway inhibitors showed a significant
blockage on the tumor growth and microenvironments in model organism (30). Vismodegib and
sonidegib are the only FDA approved drugs for different cancerous diseases. Unfortunately
Smoothened showed a drug resistance by changing its form after given multiple dosages.
Scientists acquired a different mechanism to overcome this side effect and develop other drugs
that target other than Smoothened like Gli, Hh orthologues, and Hh enzyme acyltransferase
(Hhat). In order to overcome drug resistance, further research on the key components of
signaling cascade might be crucial. In addition, studying other Hh signaling pathway
components, developing new drugs and further clinical trials on the other drugs will lead to
develop new effective drugs and better cancer treatment.
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